Developer docs
API playgroundTry for free, no card

Search company profiles

Medicspot

Full company profile

uuid0002vwr

Namestring
Medicspot
Legal namestring
DCA Medicspot Limited
Websiteurl
medicspot.co.uk
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Medicspot is a UK-based direct-to-consumer digital health platform founded in 2016 by Dr Zubair Ahmed and headquartered in London, focused on medically supervised weight loss using GLP-1 receptor agonist medications. Its product set centers on Mounjaro (tirzepatide), Wegovy injectable, and Wegovy oral tablets, with a clinical pathway that combines remote GP consultations, prescription issuance, and ongoing coaching support delivered through a subscription model priced from £89 to £329 per month. Medication dispensing is handled through a partnership with The Independent Pharmacy, while clinical governance is overseen by a UK-registered medical team including CMO Dr Abby Hyams.

Operationally, Medicspot runs a telemedicine-first model with prescribing clinicians, certified health coaches, and the regulatory registrations (CQC, GPhC, MHRA) required to prescribe and dispense weight-loss medication in the UK. The company reports a customer base of more than 227,000 and a 4.6/5 Trustpilot rating across 12,354 reviews, indicating a functioning consumer acquisition funnel and high reported customer satisfaction. Underlying technology stack includes standard SaaS tooling such as PostHog for product analytics, with no proprietary AI/ML systems disclosed.

On 30 May 2026 Medicspot was acquired by Doctor Care Anywhere (DCA) for £850,000, folding the asset into a broader virtual-care platform. Prior to that exit the company had raised approximately $3.5M across funding rounds between 2018 and 2020, and operated with a headcount in the 11–50 range. The combination of a large headline customer count against a modest acquisition price and lean headcount indicates material churn between sign-up and active subscription, which is the central financial question for any prospective investor evaluating the asset inside the DCA perimeter.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital weight management, GLP-1 medication treatment, telehealth weight loss, clinical obesity treatment, online prescription weight loss
Industry3 codes
PRIMARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code2 codes
  • Offices of Physicians6211
  • Offices of Physicians62111
SIC code3 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Digital Weight Management
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription Medication and Support Programme
TypeSubscription Recurring
Description

Monthly subscription model where customers pay for access to weight loss medication (Mounjaro, Wegovy, or oral medications) plus comprehensive support services including personal health coaching, WhatsApp community access, behavior change course, nutrition course, and 12 months aftercare support after stopping medication. Pricing varies by medication type and dosage, with first-month discounts available. Each pen/pack provides 4-week supply (injections) or 30-day supply (tablets).

medicspot.co.uk
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details3 tiers
1Wegovy Injections - starting dose 0.25mg
ModelSubscriptionBilling cadenceMonthly
Notes

0.25mg: £89 first month (regular £139), 0.5mg: £109 first month (regular £159), 1mg: £129 first month (regular £179), 1.7mg: £149 first month (regular £199), 2.4mg: £169 first month (regular £219), 7.2mg: £219 first month (regular £269). Each pen contains 4 doses (4-week supply).

medicspot.co.uk
2Mounjaro Injections - starting dose 2.5mg
ModelSubscriptionBilling cadenceMonthly
Notes

2.5mg: £149 first month (regular £199), 5mg: £169 first month (regular £219), 7.5mg: £219 first month (regular £269), 10mg: £239 first month (regular £289), 12.5mg: £259 first month (regular £309), 15mg: £279 first month (regular £329). Each KwikPen contains 4 doses (4-week supply).

medicspot.co.uk
3Wegovy Tablets - starting dose 1.5mg
ModelSubscriptionBilling cadenceMonthly
Notes

1.5mg: £89 first month (regular £139), 4mg: £109 first month (regular £159), 9mg: £129 first month (regular £179), 25mg: £179 first month (regular £229). Each pack contains 30 tablets (30-day supply). Stock expected July 2026.

medicspot.co.uk
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Medicspot is a UK direct-to-consumer digital weight management platform that delivers prescription GLP-1 and dual-agonist weight loss medications (Mounjaro/tirzepatide, Wegovy/semaglutide injections and oral tablets) combined with personal health coaching, a 16-week behaviour change course, WhatsApp peer-support community, monthly clinical reviews, and 12-month aftercare. Customers complete an online clinical assessment reviewed by GPhC-registered independent prescribers at The Independent Pharmacy, who dispense and deliver medication directly to the member's home.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 26% body weight loss achievable in clinical trials (SURMOUNT-3 for tirzepatide)
+5 more records
Product overview1 text field

Medicspot is a clinician-led digital weight management platform offering prescription GLP-1 and dual-agonist weight loss medications combined with comprehensive behavioural support. The core product portfolio includes Mounjaro (tirzepatide) injectable, Wegovy (semaglutide) injections, and Wegovy oral tablets - each providing clinically-proven weight loss through appetite regulation. These medications are complemented by a suite of support services including personal health coaching, a 16-week behaviour change course, free nutrition course, WhatsApp peer-support community, monthly clinical reviews, and 12-month aftercare support following treatment. All prescribing is conducted by The Independent Pharmacy following individual clinical assessment and review of NHS Summary Care Records. The service operates under NICE and MHRA guidance with all medical information reviewed by UK-registered doctors.

Product and service8 records
1Mounjaro (Tirzepatide) Weight Loss Injections
CategoryPrescription weight loss medication
Description

Weekly injectable GLP-1/GIP dual-agonist weight loss medication available in doses from 2.5mg to 15mg. Prescribed following Medicspot's online clinical assessment for eligible UK adults and dispensed by The Independent Pharmacy with home delivery. Targets adults with BMI 30+ or BMI 27+ with weight-related conditions.

2Wegovy Injections (Semaglutide)
CategoryPrescription weight loss medication
Description

Once-weekly semaglutide injection using pre-filled pen. GLP-1 receptor agonist that mimics natural appetite-regulating hormone. Available in doses from 0.25mg to 7.2mg. Up to 20.7% average weight loss in clinical trials. Prescribed and dispensed through The Independent Pharmacy.

3Wegovy Tablets (Oral Semaglutide)
CategoryPrescription weight loss medication
Description

Daily oral tablet form of semaglutide for weight loss. Needle-free GLP-1 treatment with doses from 1.5mg to 25mg. Each pack contains 30 tablets (30-day supply). Available by private prescription for eligible adults with BMI 30+ or 27+ with weight-related health conditions.

4Personal Health Coaching
CategoryBehavioural support service
Description

One-to-one weekly check-ins with dedicated UKHICA-certified Health Coaches. Provides motivation, side-effect management, and lifestyle change support throughout the treatment journey. Delivered to UK adult Medicspot members as part of the subscription programme.

5Behaviour Change Course
CategoryBehavioural support service
Description

16-week evidence-based programme developed by Dr Adam Abbs and Registered Dietitian Mei Wan, providing proven techniques to help patients develop sustainable healthy lifestyle habits. Included free with Medicspot subscriptions.

6Nutrition Course
CategoryBehavioural support service
Description

Free nutrition course included in the treatment plan to help patients transition off weight loss programmes and maintain healthy eating habits long-term.

7Online Clinical Assessment and Prescribing Service
CategoryClinical service
Description

Detailed online assessment covering medical history, BMI, weight goals, mental health, eating behaviour, and lifestyle factors. Reviewed by UK-registered GPhC independent prescribers at The Independent Pharmacy before any prescription is issued, with NHS Summary Care Record access and patient GP notification.

812-Month Aftercare Support
CategoryClinical aftercare service
Description

NICE-aligned 12-month structured aftercare support programme for members who have been with Medicspot for at least 4 months. Includes weekly check-ins for the first 3 months after stopping medication, monthly for the following 9 months, plus ongoing behavioural support to sustain weight loss.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

The Independent Pharmacy is Medicspot's exclusive prescribing partner, handling all clinical assessments, prescription issuance, and medication dispensing. TIP is CQC-registered for remote clinical prescribing and GPhC-registered for pharmacy dispensing. They conduct independent clinical reviews, access NHS Summary Care Records for safety verification, and notify patients' NHS GPs of prescriptions. TIP also handles all clinical and pharmacy-related complaints.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Doctor Care Anywhere acquired Medicspot for a purchase price of £850,000. The acquisition gives DCA immediate presence in the UK's rapidly expanding digital health weight management market and strengthens its direct-to-consumer healthcare offering. This transaction supports DCA's growth strategy by creating cross-selling opportunities across its broader healthcare portfolio.

Strategic tierMinorTypeOthers
Description

Weightmans, a Liverpool-headquartered law firm, advised Doctor Care Anywhere on its acquisition of Medicspot for £850,000.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Juniper
TypeDirect peer
Description

UK-based subscription telehealth provider focused on medically supervised weight loss using GLP-1 medications combined with coaching. Most direct head-to-head competitor to Medicspot with overlapping UK D2C audience and bundled medication-plus-support proposition.

TypeDirect peer
Description

UK digital health subscription platform offering weight-loss treatment alongside men's health services. Directly comparable D2C subscription model with prescribing, coaching, and recurring medication revenue targeting the same UK adult demographic.

TypeDirect peer
Description

Established UK/European online clinic offering weight-loss consultations and prescriptions via telehealth. Competes on similar online assessment-to-prescription flow with comparable pricing and regulatory positioning in the UK GLP-1 market.

TypeDirect peer
Description

UK digital weight-loss clinic providing GLP-1 prescriptions with clinician oversight and ongoing support. Closely mirrors Medicspot's bundled medication-plus-coaching value proposition in the same UK D2C channel.

5Pharmacy2U
TypeDirect peer
Description

UK online pharmacy and prescription service that has expanded into weight-loss treatment programs. Comparable in dispensing infrastructure and clinical pathway but adds NHS-aligned prescription fulfillment scale.

TypeDirect peer
Description

UK digital weight-management program combining behavioral coaching with optional medication support. Closely comparable multi-modal weight-loss proposition with an emphasis on behavior change layered over clinical intervention.

TypeBroad incumbent
Description

UK high-street pharmacy chain's online consultation service covering weight loss alongside a broad primary care portfolio. Offers overlapping weight-loss prescribing capability but as part of a much wider healthcare offering.

TypeOthers
Description

Medicspot's exclusive prescribing and dispensing partner (CQC/GPhC-registered). Operates as both supplier and adjacent online clinic in its own right; an ecosystem participant rather than a head-to-head competitor.

TypeBroad incumbent
Description

US-listed broad telehealth platform with a fast-growing weight-loss vertical using GLP-1 medications and coaching. Comparable subscription D2C model at scale, though US-focused and operating across many conditions beyond weight.

10Noom
TypeEmerging player
Description

Global digital weight-management platform that has expanded into GLP-1 prescribing via Noom Med. Comparable in combining behavioral coaching with medication pathways, though predominantly US-anchored and an emerging player in the UK.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicspot

Digital Weight Managementmedicspot.co.uk

What Medicspot does

Medicspot is a UK-based direct-to-consumer digital health platform founded in 2016 by Dr Zubair Ahmed and headquartered in London, focused on medically supervised weight loss using GLP-1 receptor agonist medications. Its product set centers on Mounjaro (tirzepatide), Wegovy injectable, and Wegovy oral tablets, with a clinical pathway that combines remote GP consultations, prescription issuance, and ongoing coaching support delivered through a subscription model priced from £89 to £329 per month. Medication dispensing is handled through a partnership with The Independent Pharmacy, while clinical governance is overseen by a UK-registered medical team including CMO Dr Abby Hyams.

Operationally, Medicspot runs a telemedicine-first model with prescribing clinicians, certified health coaches, and the regulatory registrations (CQC, GPhC, MHRA) required to prescribe and dispense weight-loss medication in the UK. The company reports a customer base of more than 227,000 and a 4.6/5 Trustpilot rating across 12,354 reviews, indicating a functioning consumer acquisition funnel and high reported customer satisfaction. Underlying technology stack includes standard SaaS tooling such as PostHog for product analytics, with no proprietary AI/ML systems disclosed.

On 30 May 2026 Medicspot was acquired by Doctor Care Anywhere (DCA) for £850,000, folding the asset into a broader virtual-care platform. Prior to that exit the company had raised approximately $3.5M across funding rounds between 2018 and 2020, and operated with a headcount in the 11–50 range. The combination of a large headline customer count against a modest acquisition price and lean headcount indicates material churn between sign-up and active subscription, which is the central financial question for any prospective investor evaluating the asset inside the DCA perimeter.

Medicspot firmographics

Firmographics
Name
Medicspot
Legal name
DCA Medicspot Limited
Website
https://medicspot.co.uk
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

Medicspot industry classification

Industry
Product category
Digital Weight Management
NAICS
Offices of Physicians (6211), Offices of Physicians (62111)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Digital weight management
  • GLP-1 medication treatment
  • Telehealth weight loss
  • Clinical obesity treatment
  • Online prescription weight loss

Where Medicspot is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Medicspot business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Subscription Medication and Support Programme: Monthly subscription model where customers pay for access to weight loss medication (Mounjaro, Wegovy, or oral medications) plus comprehensive support services including personal health coaching, WhatsApp community access, behavior change course, nutrition course, and 12 months aftercare support after stopping medication. Pricing varies by medication type and dosage, with first-month discounts available. Each pen/pack provides 4-week supply (injections) or 30-day supply (tablets).

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyWegovy Injections - starting dose 0.25mg
SubscriptionMonthlyMounjaro Injections - starting dose 2.5mg
SubscriptionMonthlyWegovy Tablets - starting dose 1.5mg

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Medicspot product offering

Product offering

Core offering

Medicspot is a UK direct-to-consumer digital weight management platform that delivers prescription GLP-1 and dual-agonist weight loss medications (Mounjaro/tirzepatide, Wegovy/semaglutide injections and oral tablets) combined with personal health coaching, a 16-week behaviour change course, WhatsApp peer-support community, monthly clinical reviews, and 12-month aftercare. Customers complete an online clinical assessment reviewed by GPhC-registered independent prescribers at The Independent Pharmacy, who dispense and deliver medication directly to the member's home.

Product overview

Medicspot is a clinician-led digital weight management platform offering prescription GLP-1 and dual-agonist weight loss medications combined with comprehensive behavioural support. The core product portfolio includes Mounjaro (tirzepatide) injectable, Wegovy (semaglutide) injections, and Wegovy oral tablets - each providing clinically-proven weight loss through appetite regulation. These medications are complemented by a suite of support services including personal health coaching, a 16-week behaviour change course, free nutrition course, WhatsApp peer-support community, monthly clinical reviews, and 12-month aftercare support following treatment. All prescribing is conducted by The Independent Pharmacy following individual clinical assessment and review of NHS Summary Care Records. The service operates under NICE and MHRA guidance with all medical information reviewed by UK-registered doctors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mounjaro (Tirzepatide) Weight Loss Injections Weekly injectable GLP-1/GIP dual-agonist weight loss medication available in doses from 2.5mg to 15mg. Prescribed following Medicspot's online clinical assessment for eligible UK adults and dispensed by The Independent Pharmacy with home delivery. Targets adults with BMI 30+ or BMI 27+ with weight-related conditions.
  • Wegovy Injections (Semaglutide) Once-weekly semaglutide injection using pre-filled pen. GLP-1 receptor agonist that mimics natural appetite-regulating hormone. Available in doses from 0.25mg to 7.2mg. Up to 20.7% average weight loss in clinical trials. Prescribed and dispensed through The Independent Pharmacy.
  • Wegovy Tablets (Oral Semaglutide) Daily oral tablet form of semaglutide for weight loss. Needle-free GLP-1 treatment with doses from 1.5mg to 25mg. Each pack contains 30 tablets (30-day supply). Available by private prescription for eligible adults with BMI 30+ or 27+ with weight-related health conditions.
  • Personal Health Coaching One-to-one weekly check-ins with dedicated UKHICA-certified Health Coaches. Provides motivation, side-effect management, and lifestyle change support throughout the treatment journey. Delivered to UK adult Medicspot members as part of the subscription programme.
  • Behaviour Change Course 16-week evidence-based programme developed by Dr Adam Abbs and Registered Dietitian Mei Wan, providing proven techniques to help patients develop sustainable healthy lifestyle habits. Included free with Medicspot subscriptions.
  • Nutrition Course Free nutrition course included in the treatment plan to help patients transition off weight loss programmes and maintain healthy eating habits long-term.
  • Online Clinical Assessment and Prescribing Service Detailed online assessment covering medical history, BMI, weight goals, mental health, eating behaviour, and lifestyle factors. Reviewed by UK-registered GPhC independent prescribers at The Independent Pharmacy before any prescription is issued, with NHS Summary Care Record access and patient GP notification.
  • 12-Month Aftercare Support NICE-aligned 12-month structured aftercare support programme for members who have been with Medicspot for at least 4 months. Includes weekly check-ins for the first 3 months after stopping medication, monthly for the following 9 months, plus ongoing behavioural support to sustain weight loss.

Quantifiable outcome

  • Up to 26% body weight loss achievable in clinical trials (SURMOUNT-3 for tirzepatide)
  • +5 more outcomes

Companies that use Medicspot

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Medicspot technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature4 records

Medicspot partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • The Independent Pharmacy (TIP)coreImplementation/ SI/ Consulting PartnerThe Independent Pharmacy is Medicspot's exclusive prescribing partner, handling all clinical assessments, prescription issuance, and medication dispensing. TIP is CQC-registered for remote clinical prescribing and GPhC-registered for pharmacy dispensing. They conduct independent clinical reviews, access NHS Summary Care Records for safety verification, and notify patients' NHS GPs of prescriptions. TIP also handles all clinical and pharmacy-related complaints.
  • Doctor Care Anywhere (DCA)coreStrategic or Co-development PartnerDoctor Care Anywhere acquired Medicspot for a purchase price of £850,000. The acquisition gives DCA immediate presence in the UK's rapidly expanding digital health weight management market and strengthens its direct-to-consumer healthcare offering. This transaction supports DCA's growth strategy by creating cross-selling opportunities across its broader healthcare portfolio.
  • Weightmans LLPminorOthersWeightmans, a Liverpool-headquartered law firm, advised Doctor Care Anywhere on its acquisition of Medicspot for £850,000.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Medicspot competitors and assessment

Company assessment

Direct peers

  • Juniper: UK-based subscription telehealth provider focused on medically supervised weight loss using GLP-1 medications combined with coaching. Most direct head-to-head competitor to Medicspot with overlapping UK D2C audience and bundled medication-plus-support proposition.
  • Numan: UK digital health subscription platform offering weight-loss treatment alongside men's health services. Directly comparable D2C subscription model with prescribing, coaching, and recurring medication revenue targeting the same UK adult demographic.
  • Zava: Established UK/European online clinic offering weight-loss consultations and prescriptions via telehealth. Competes on similar online assessment-to-prescription flow with comparable pricing and regulatory positioning in the UK GLP-1 market.
  • Voy: UK digital weight-loss clinic providing GLP-1 prescriptions with clinician oversight and ongoing support. Closely mirrors Medicspot's bundled medication-plus-coaching value proposition in the same UK D2C channel.
  • Pharmacy2U: UK online pharmacy and prescription service that has expanded into weight-loss treatment programs. Comparable in dispensing infrastructure and clinical pathway but adds NHS-aligned prescription fulfillment scale.
  • Second Nature: UK digital weight-management program combining behavioral coaching with optional medication support. Closely comparable multi-modal weight-loss proposition with an emphasis on behavior change layered over clinical intervention.

Broad incumbents

  • LloydsPharmacy Online Doctor: UK high-street pharmacy chain's online consultation service covering weight loss alongside a broad primary care portfolio. Offers overlapping weight-loss prescribing capability but as part of a much wider healthcare offering.
  • Hims & Hers: US-listed broad telehealth platform with a fast-growing weight-loss vertical using GLP-1 medications and coaching. Comparable subscription D2C model at scale, though US-focused and operating across many conditions beyond weight.

Others

  • The Independent Pharmacy: Medicspot's exclusive prescribing and dispensing partner (CQC/GPhC-registered). Operates as both supplier and adjacent online clinic in its own right; an ecosystem participant rather than a head-to-head competitor.

Emerging players

  • Noom: Global digital weight-management platform that has expanded into GLP-1 prescribing via Noom Med. Comparable in combining behavioral coaching with medication pathways, though predominantly US-anchored and an emerging player in the UK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Medicspot social profiles

Digital presence

Medicspot compliance and trust

Trust signal

Compliance4 records

Medicspot financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicspot leadership team

Management profile

Number of profiles

Profiles6 records

Medicspot funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicspot M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicspot

What does Medicspot do?

Medicspot is a UK direct-to-consumer digital weight management platform that delivers prescription GLP-1 and dual-agonist weight loss medications (Mounjaro/tirzepatide, Wegovy/semaglutide injections and oral tablets) combined with personal health coaching, a 16-week behaviour change course, WhatsApp peer-support community, monthly clinical reviews, and 12-month aftercare. Customers complete an online clinical assessment reviewed by GPhC-registered independent prescribers at The Independent Pharmacy, who dispense and deliver medication directly to the member's home.

Is Medicspot a public or private company?

Medicspot is a private company. It is classified as corporate owned and is currently acquired.

When was Medicspot founded?

Medicspot was founded in 2016. It employs 11 to 50 people.

Where is Medicspot based?

Medicspot is headquartered in London, United Kingdom, in the Europe region.

How does Medicspot make money?

One revenue line is on record: subscription Medication and Support Programme.

Who are Medicspot's main competitors?

Direct peers on record are Juniper, Numan, Zava, Voy, Pharmacy2U and Second Nature. Broad incumbents are LloydsPharmacy Online Doctor and Hims & Hers. The Independent Pharmacy is listed as an others. Noom is listed as an emerging player.

Does Medicspot have an API?

No public API is recorded for Medicspot.

What industry is Medicspot in?

Medicspot's product category is Digital Weight Management. Its primary akta.pro industry code is HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing, with a secondary code of HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM). Its NAICS code is 6211 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals